PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104638
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2104638
Artificial Intelligence in Bioinformatics Market size was valued at US$ 3,780.5 Million in 2025, expanding at a CAGR of 24.6% from 2026 to 2033.
AI in bioinformatics implies the use of different techniques of artificial intelligence like machine learning, deep learning, natural language processing, etc., for the analysis of biological information for the purpose of speeding up genomics studies, improving predictions in protein modeling, and developing drugs and personalized therapies. Bioinformatics systems with the use of AI enable the collection and analysis of vast quantities of clinical, genomic, proteomic, and transcriptomic information much more effectively than conventional analyses. The growing popularity of AI bioinformatics systems is associated with investments made in genome research as well as an ever-increasing demand for the solutions used in drug development. In addition, the effective collaboration of educational institutions, biotechnology companies, and pharma corporations using the technologies will spur the development of medical diagnostics and markers and the creation of personalized treatments.
Artificial Intelligence in Bioinformatics Market- Market Dynamics
Growing Investments in Genomics Research and AI-Driven Drug Discovery Accelerating Market Growth
The increasing generation of biological data via Next-Generation Sequencing (NGS), omics science, and precision medicine is greatly propelling the adoption of Artificial Intelligence in Bioinformatics. The increasing amount and complexity of genomic, proteomic, and clinical data makes AI-enabled analytical tools increasingly popular among research institutes and pharma companies for proper management of the data. They help detect disease markers using machine learning and deep learning algorithms, predict protein structures, understand genomic variants, streamline the process of drug discovery and other operations. Besides, an increasing occurrence of chronic diseases along with the growing popularity of personalized medicine is increasing the adoption of AI-based solutions for bioinformatics in clinical research and diagnostics. Additionally, the increasing occurrences of chronic diseases, as well as the current trend of personalized medicine, make healthcare specialists move to the adoption of AI-based bioinformatics.
For instance, the United States National Institutes of Health (NIH) released a statement saying that the All of Us Research Program had made available the biggest data set to date, which consists of data of over 747,000 people and is among the world's biggest databases containing integrated genomic and electronic health record (EHR) data. The release contained more than 535,000 whole genome sequences paired with almost 482,000 electronic health records, providing an unprecedented amount of genomic and clinical information for biomedical research. The program will use cutting-edge bioinformatics, genomics sequencing and AI-powered analytical techniques to enhance the speed of precision medicine research and understanding of disease risk and response to treatment. These massive projects rely on the government to fund the development of AI-driven bioinformatics platforms that handle intricate biomedical data and facilitate next-generation research in healthcare. The need for AI-driven bioinformatics platforms that efficiently manage the complexities of biomedical data has been raised in the context of such large-scale initiatives.
The Global Artificial Intelligence in Bioinformatics Market is segmented on the basis of Component, Application, End User, Technology, and Region.
From an application perspective, Drug Discovery & Development is dominating the Artificial Intelligence in Bioinformatics Market because of increasing adoption of AI algorithms for the purposes of target identification, molecular modeling, compound screening, biomarker identification, and optimization of clinical trials. Thanks to the use of bioinformatics technology based on Artificial Intelligence, companies working in the pharmaceutical industry are able to easily deal with massive amounts of genomic and proteomic data and facilitate the drug discovery process. The increasing adoption of these solutions within the pharmaceutical industry, particularly within the personalized medicine, biologics, and gene therapies markets, is driving the market. Increasing utilization of these services in pharmaceutical research, specifically in the personalized medicine, biologics and gene-based therapy markets, is yet another important market driver. For Example, in May 2024, NVIDIA partnered with IQVIA for the development of AI-based solutions for drug discovery and clinical development, using the technology of NVIDIA as well as healthcare data and analytics from IQVIA.
With Technology, Machine Learning (ML) is still leading the market as it discovers the hidden patterns in genomic, transcriptomic and proteomic data, which lead to accurate prediction of disease, variant classification and precision medicine research. For example, the National Human Genome Research Institute (NHGRI) is seeing the growing use of machine learning to analyze genome data produced by large-scale genome sequencing projects, in a range of disease gene identification, functional genomics and precision medicine research applications. As machine learning algorithms continue to be used more in biomedical research, their widespread adoption of AI-based bioinformatics solutions around the globe is likely to be further propelled.
Artificial Intelligence in Bioinformatics Market- Geographical Insights
North America is the major region holds largest market share in the Artificial Intelligence in Bioinformatics Market, due to the presence of advanced biotechnology infrastructure, pharmaceutical research, genome sequencing, and substantial investments in AI applications in the life sciences industry. With the rising requirement of AI-enabled bioinformatics tools for analyzing genomic information, finding biomarkers, formulating precision medicines and drug discovery, this market is growing. The National Center for Biotechnology Information (NCBI) is a component of the National Library of Medicine (NLM) at the National Institutes of Health (NIH) and offers various free bioinformatics databases and tools including GenBank, BLAST, and SRA. These tools and databases are being widely used across the world by the scientific community for genomic data analysis, sequence analysis and computational biology research through the use of AI. With the support of the government, the biological databases are being used for extensive analysis of biological data and have been instrumental in adopting AI-based bioinformatics solutions across research institutes, pharmaceutical companies and healthcare organizations in North America.
Europe is also a major market, marked by rising investments in genomics, personalized medicine and biomedical data analytics, with collaborative research projects and digital health programs playing a key part. In the academic world, pharmaceutical and healthcare sectors, the region is seeing increasing application of AI-infused bioinformatics solutions for better disease research and faster therapeutic advancements. For instance, the European Bioinformatics Institute (EBI), which is part of the European Molecular Biology Laboratory (EMBL), provides open access biological databases, bioinformatics tools compatible with AI, and advanced computational capabilities for data integration and research on proteins and genomics in Europe. All these initiatives are contributing to the adoption of bioinformatics platforms using AI technology in Europe.
The Artificial Intelligence in Bioinformatics Market is highly competitive, wherein the leading biotech and healthcare technologies, cloud computing analytics, and AI companies are aggressively involved in offering their AI-enabled solutions in the bioinformatics industry. Leading organizations in the market include Illumina, Inc., NVIDIA Corporation, Thermo Fisher Scientific Inc., QIAGEN N.V., IBM Corporation, Microsoft Corporation, Google LLC, Oracle Corporation, SOPHiA GENETICS, DNAnexus, Tempus AI, BenevolentAI, Insilico Medicine, BioSymetrics Inc., and Deep Genomics. To gain a competitive edge, firms are spending on AI-enabled genomic analysis tools, protein structure prediction tools, drug discovery software, and precision medicine solutions. Strategic partnerships and product innovations, acquisitions and cloud-based bioinformatics have enabled organizations to accelerate biomedical research, improve clinical decision-making and enable the analysis of large-scale bioinformatics and multi-omics data.
In February 2026, The U.S. Department of Agriculture's Animal and Plant Health Inspection Service has awarded Utah State University a $1.9 million contract to create new treatments, drugs and therapies for avian influenza. Associate Professor Rakesh Kaundal led the project using approaches of AI, machine learning and advanced bioinformatics.
In April 2025, Tempus AI entered into new multiyear strategic partnerships with AstraZeneca and Pathos AI for a multimodal foundation model in oncology. The partnership took advantage of Tempus' de-identified oncology information to provide biological and clinical insights, drug discovery and therapeutic development. Included in the agreements were $200 million in data licensing and model development fees.